111 Migraine with and without aura in relation to the menstrual cycle 5 Migraine course during hormonal milestones (cross-sectional data) Oral contraceptive use (past or present) was reported by 197 (93.8%) women with MA and 298 (94.3%) women with MO. The main reason for oral contraceptive use was contraception in 57.4% of participants (58.4% MO versus 55.8% MA), migraine in 8.7% (8.1% MO and 9.6% MA), and non-specified in 33.9% of the respondents (33.6% MO versus 34.5% MA) (p = 0.774). There was no difference in reported effect on migraine frequency during oral contraceptive use between women with MO and MA (Figure 2, p = 0.169). Figure 2. Effect of oral contraceptive use, pregnancy and breastfeeding on migraine frequency for all patients, stratified by diagnosis. (a) Oral contraceptive use; (b) pregnancy and (c) breastfeeding. A total of 82 of 118 women with MA who had been pregnant, reported improvement of migraine frequency (69.5%) versus 155 of 196 women with MO that had been pregnant (79.1%). There was a significant association between migraine diagnosis (MO versus MA) and migraine frequency during pregnancy (p = 0.015). A total of 39 of 77 women with MA who had breastfed in the past, reported improvement of migraine frequency (50.6%) versus 100 of 150 women with MO that had breastfed (66.7%). There was a significant association between migraine diagnosis (MO versus MA) and migraine frequency during breastfeeding (p = 0.004).
RkJQdWJsaXNoZXIy MjY0ODMw